ACM
CUE icon

ADAR1 Capital Management’s Cue Biopharma CUE Stock Holding History

ADAR1 Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Buy
+55,193
New +$1.25M 0.08% 146

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

ADAR1 Capital Management's CUE Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Cue Biopharma (CUE) in Q2 2026: 55,193 shares worth $1.74M. The stake represents 0.08% of the portfolio and ranks #146 among its holdings.

46 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • ADAR1 Capital Management held 55,193 shares of Cue Biopharma worth $1.74M as of Q2 2026.
  • Cue Biopharma was a new ADAR1 Capital Management position in Q2 2026.
  • Cue Biopharma made up 0.08% of ADAR1 Capital Management's portfolio in Q2 2026, its #146 holding.
  • 46 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.